Skip to main content
. 2021 Dec 3;11:780118. doi: 10.3389/fonc.2021.780118

Figure 9.

Figure 9

Illustration of the mechanism underlying chidamide induced follicular lymphoma growth inhibition. Chidamide exerts antitumor activity toward FL both in vitro and in vivo, potentially by targeting the PDK1-Akt-P27-CDK2 pathway and triggering caspase dependent apoptosis, finally markedly blocking cells in the G0/G1 phase.